State Street Corp Cuts Stake in Hookipa Pharma Inc (NASDAQ:HOOK)

State Street Corp lessened its holdings in Hookipa Pharma Inc (NASDAQ:HOOK) by 90.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,967 shares of the company’s stock after selling 152,723 shares during the period. State Street Corp owned approximately 0.14% of Hookipa Pharma worth $73,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of HOOK. Renaissance Technologies LLC boosted its holdings in Hookipa Pharma by 38.4% in the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares during the period. Ikarian Capital LLC acquired a new stake in Hookipa Pharma in the 3rd quarter valued at about $228,000. Finally, Acadian Asset Management LLC boosted its stake in shares of Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after buying an additional 108,844 shares during the period. Institutional investors and hedge funds own 63.88% of the company’s stock.

Hookipa Pharma Stock Performance

HOOK opened at $1.86 on Friday. The business’s 50-day simple moving average is $2.67 and its 200-day simple moving average is $4.28. The company has a market cap of $22.42 million, a P/E ratio of -0.50 and a beta of 0.71. Hookipa Pharma Inc has a one year low of $1.75 and a one year high of $10.50.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HOOK. Royal Bank of Canada lowered shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and cut their target price for the stock from $48.00 to $2.00 in a research note on Friday, December 20th. JMP Securities dropped their price objective on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 21st.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.